Journals / Retina-Vitreus / 2010 / Cilt: 18 - Sayı: 1

Proliferatif Diabetik Retinopatide Kombine Tedavi Olarak İntravitreal Bevacizumab ve Panretinal Fotokoagülasyon

Intravitreal Bevacizumab and Panretinal Photocoagulation as Combined Treatment in Proliferative Diabetic Retinopathy

Pages
52–55
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Adding bevacizumab accelerates the time of inactivity in the angiography, avoids up to twice the time for reapplying laser and is 3 times less likely to be retreated

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To document proliferative control of fluorescein angiography in diabetic retinopathy after intravitreal bevacizumab and hemiretinal photocoagulation, compared to a complete panretinal photocoagulation in the contralateral eye.
📊
Key Findings & Data:The right eye received intravitreal bevacizumab and a single session of 800 scattered laser spots.
💡
Conclusion & Impact:Adding bevacizumab accelerates the time of inactivity in the angiography, avoids up to twice the time for reapplying laser and is 3 times less likely to be retreated
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To document proliferative control of fluorescein angiography in diabetic retinopathy after intravitreal bevacizumab and hemiretinal photocoagulation, compared to a complete panretinal photocoagulation in the contralateral eye. Material and Methods: Patients with bilateral and symmetrical proliferative diabetic retinopathy without history of previous treatment were included. The right eye received intravitreal bevacizumab and a single session of 800 scattered laser spots. The left eye underwent a full 1,600 laser panretinal photocoagulation. Angiography was performed monthly for 6 months to document inactivity of the diabetic retinopathy. Statistical significance in between eyes of persistent angiographic activity, time of reapplication and also number of retreatments with panretinal photocoagulation were analyzed using T-tests set as p<0.05.Results: 109 patients were enrolled. In the first month, 16.6% of right eyes presented activity, compared to 34% of left eyes (p<0.05); the difference was statistically significant up to the 4th month. In the 5th and 6th months, the activity in both eyes was not statistically significant. The median time of reapplying laser in the right eyes was 112 days, compared to 65 days in the left. In the first four months, the left eye was retreated 3 times more than the right eye.Conclusions: Applying bevacizumab with half panretinal photocoagulation is more effective in inactivating the proliferative diabetic retinopathy, compared to a full panretinal photocoagulation up to the 4th month. Adding bevacizumab accelerates the time of inactivity in the angiography, avoids up to twice the time for reapplying laser and is 3 times less likely to be retreated

Özet

Amaç: Diabetik retinopatide intravitreal bevacizumab ve hemiretinal fotokoagülasyon tedavisinin, diğer gözde uygulanan tam panretinal fotokoagülasyona göre floresein anjiografide proliferatif kontrolünün ortaya konulmasıdır.Gereç ve Yöntem: Daha önce herhangi bir tedavi hikayesi olmayan, bilateral ve simetrik proliferatif diabetik retinopatili olgular çalışmaya dahil edildi. Sağ göze intravitreal bevacizumab ve tek seansta 800 atım lazer uygulandı. Sol göze ise 1600 atım tam panretinal fotokoagülasyon uygulandı. 6 ay boyunca her ay diabetik retinopatinin inaktivasyonunun gösterilmesi için anjiografi yapıldı. Dirençli anjiografik aktivite, tekrar uygulama zamanı ve ayrıca panretinal fotokoagülasyon tedavi sayıları açısından gözler arasındaki farklar, istatistiksel anlamlılık ölçütü p<0.05 alınarak T-testi ile analiz edildi.Bulgular: 109 hasta çalışmaya dahil edildi. İlk ayda, sağ gözlerin %16.6'sında, sol gözlerin %34'ünde aktivite vardı (p<0.05); bu fark 4. aya kadar istatistiksel olarak anlamlıydı. 5. ve 6. aylarda her iki gözde aktivite istatistiksel olarak anlamlı değildi. Sağ gözlerde ortalama tekrar lazer uygulama zamanı 112 günken; sol gözlerde 65 gündü. İlk dört ayda sol göz, sağ göze göre 3 kat daha fazla tedavi edildi.Sonuç: İlk 4 aya kadar, proliferatif diabetik retinopatinin inaktifleştirilmesinde, yarım panretinal koagülasyon ile beraber bevacizumab uygulaması, tam panretinal koagülasyon uygulamasına göre daha etkilidir. Bevacizumabın eklenmesi, anjiografide inaktivite oluşumunu hızlandırmakta, tekrar lazer uygulama zamanını iki kata kadar uzatmakta ve 3 kat daha az yeniden tedavi gerekmektedir

🔖

Cite This Article

FULDA, E., ARIZA, E., LOPEZ, A., GRAUE, F. (2010). Proliferatif Diabetik Retinopatide Kombine Tedavi Olarak İntravitreal Bevacizumab ve Panretinal Fotokoagülasyon. Retina-Vitreus, Cilt: 18 - Sayı: 1, 52–55. https://ajindex.com/articles/308058

References (15)

  1. Ferrara N.: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:581-611
  2. Ferrara N, Davis-Smyth T.: The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25
  3. Adamis AP, Shima DT.: The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111-118
  4. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and ot-her retinal disorders. N Engl J Med. 1994;331:1480-1487
  5. Adamis, et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71
  6. S.C. Kaufman, et al.: Factors Associated with visual outcome after photocoagulation for diabetic retinopathy. Diabetic Retinopathy Study Report #13. Invs Ophtha and Visu Scien. 1989;30. No 1
  7. L.I. Rand, et al.: Factors influencing the development of visual loss in advanced diabetic retinopaty. Diabetic Retinopathy Study Re-port #10. Invs Ophtha and Visu Scien. 1988;28. No 2
  8. P.J. Rosenfeld, et al.: Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical Study. Ophthal. 2005;6:1035-1047
  9. R. Avery, et al.: Intravitreal Bevacizumab (Avastin) for Neovascu-lar Age-Related Macular Degeneration, Ophthalm. 2006;3:363-372
  10. Y. Chen, et al.: Intravitreal Bevacizumab for Neovascular Age-related Macular Degeneration: A Short-term Study, Amer Jour of Ophthal. 2007;143:510-512
  11. Wai-Man Chan, et al.: Intravitreal Bevacizumab for Choroidal Neovascularization Secondary to Central Serous Chorioretino-pathy, Secondary to Punctate Inner Choroidopathy, or of Idiopat-hic Origin, Amer Jour of Ophthal. 2007;143:977-983
  12. J. F. Arevalo, et al.: Primary intravitreal bevacizumab for the ma-nagement of pseudophakic cystoid macular edema: Pilot study of the Pan-American Collaborative Retina Study Group. Jour of Ca-tar & Refrac Surg. 2007;33:2098-2105
  13. Haritoglou C, et al.: Intravitreal bevacizumab (Avastin) the-rapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005
  14. Ates Yanyali, et al.: Bevacizumab (avastin) for Diabetic Macu-lar Edema in Previously Vitrectomized Eyes. Amer Jour of Ophth. 2007;144:124-126
  15. Martin S. Spitzer, et al.: Efficacy of intravitreal bevacizumab in tre-ating postoperative pseudophakic cystoid macu